The Influence of Mycophenolate Mofetil and Azathioprine on the Same Cadaveric Donor Renal Transplantation by Joh, Jae Won et al.
INTRODUCTION
Acute allograft rejection is the most important factor for
early graft loss and appears to increase the risk of graft failure
in cadaveric kidney transplantation (1). Furthermore, non-
immunologic factors such as donor and recipient’s age, sex,
donor source and immunosuppressive regimens influence allo-
graft prognosis (2). Mycophenolate mofetil (MMF) is the mor-
pholinoethly ester of mycophenolic acid (MPA).
MMF is rapidly converted into MPA after oral administra-
tion and absorbed in the gut. MPA is a potent, reversible, un-
competitive inhibitor of inosine monophosphate dehydroge-
nase, and thus MMF acts as a selective inhibitor of T- and B-
cell proliferation by blocking the production of guanosine
nucleotides and interfering with the glycosylation of adhesion
molecules. Four clinical trials evaluated the efficacy of MMF
in the prevention of renal allograft rejection, using the inci-
dence of biopsy-proven acute rejection or treatment failure at
6 months after transplantation as the primary efficacy end-
point. Three of the four studies compared the triple-therapy
regimen of cyclosporine (CsA), corticosteroids, and MMF (one
study with and one study without anti-thymocyte globulin
[ATG] induction) with a classic triple-therapy regimen com-
posed of azathioprine (AZA) (with or without ATG), CsA, and
corticosteroids (1, 3, 4). In the 4th study, MMF-based triple
therapy was compared with a dual therapy consisting of place-
bo, CsA, and corticosteroids (5). All studies concluded that
MMF reduced the incidence of biopsy-proven acute rejection
or treatment failure significantly during the first 6 months.
Before the establishment of KONOS (Korean Network of
Organ Sharing), February 2000, all the organ distributions
of cadaver donors were the responsibility of the organ procure-
ment hospital which is basically identical to transplantation
hospital. Accordingly, only the following case was included
in our study: when a cadaver turned up in our hospital and
the recipient also underwent transplantation in our hospital.
In order to evaluate how immunosuppressive agents such as
MMF and AZA would influence the outcome of the graft kid-
ney, we analyzed the incidence of acute rejection episodes, cy-
tomegalovirus (CMV) infection within the first 6 months fol-
lowing renal transplantation and the 5 yr graft survival rate
after minimizing the influences of donor factors by grafting
from the same cadaveric donor. 
MATERIALS AND METHODS
The study population consisted of 68 consecutively admitted
patients who were grafted from 34 cadaveric donors from May
1998 to January 2000 at Samsung Medical Center. Pre-opera-
tively, the study protocol was explained in detail to all patients
and an informed consent to perform the study was obtained.
The experiment was carried out after factors involving do-
nors, the operation itself and patient control following oper-
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In order to evaluate whether immunosuppressive agents such as mycophenolate
mofetil (MMF) and azathioprine would differently influence the outcome of the renal
transplants, we prospectively analyzed the incidence of acute rejection episodes,
cytomegalovirus infection within the first 6 months following renal transplantation and
5 yr graft survival rate after minimizing influences of donor factors by grafting the same
cadaveric donor kidney. There was no significant difference in sex, HLA mismatch,
cold ischemic time, and patients’ weight between the two groups. Contrary to the
previous studies which demonstrated that MMF could lower the incidence of acute
rejection episodes and improved graft survival rate, the two groups showed no sig-
nificant difference in the incidence of acute rejection episodes and 5-yr graft survival
rate as well. This discrepancy in these results might explain that donor factors could
be important to cadaveric renal transplantation. Thus, we suggest that the influences
of donor factors should be considered in further clinical studies of cadaveric renal
transplantation.
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ation were minimized. When two cases of kidney transplan-
tation took place from the same cadaveric donor in our hospi-
tal, transplantation was performed on a first come first served
base. MMF was administered to the early-transplanted patient
and AZA to the following patient, and vice versa in the next
case. The patients orally received MMF (1.5 g/d) or AZA
(100-130 mg/d) and the dose was regulated by the patient’s
conditions. If we suspect an acute rejection, graft biopsy was
performed to diagnose the acute rejection. If it was not avail-
able, clinical impressions such as elevated serum creatinine
level and decreased urine output, and radiological results sup-
ported by Doppler ultrasound were used for the diagnosis of
acute rejection. Acute rejection, graft loss, death, and discon-
tinuation of study drugs were defined as treatment failure.
Patient and graft survival rates were compared between the
two groups. In the case of graft nephrectomy or taking hemo-
dialysis over 6 weeks post-transplant, they were categorized
as graft loss. CMV antigenemia test and clinical evidence were
used to compare CMV infection rate between the two groups.
Patients who developed CMV disease or a high level of CMV
infection (antigenemia assay >50/400,000 mononuclear cells)
were treated with an antiviral agent such as gancilovir.
Kaplan-Meier method was used for the analysis of graft sur-
vival rate. Recipient’s age, body weight, HLA mismatching,
and cold ischemic time were tested by Mann-Whitney test
between groups. Chi-square test was applied to evaluate sex
and underlying disease variation. p-values less than 0.05 were
considered statistically significant in all results.
RESULTS
In the comparison of demographics and clinical character-
istics, the mean age of MMF and AZA groups were 42.2 and
35.4 yr, respectively, showing a significant difference (p=.015,
Table 1). However, there were no significant differences in
sex, underlying diseases, frequency of pretransplant PRA level
(≥20%), HLA mismatching, cold ischemic time, donor and
recipient’s CMV serologic status and underlying disease, and
ABO compatibility (Table 1). 
Treatment failure occurred in 12 patients (35.3%) of the
MMF group by 6 months after transplantation, when com-
pared with 11 patients (32.4%) in the AZA group without
statistical significance (p>0.05). The frequency of clinical or
biopsy-proven rejection treated with steroid pulse therapy were
29.4% and 20.6% in MMF and AZA groups, respectively
(p>0.05). Two patients in MMF and one patient in AZA expe-
rienced graft loss during the 6-month follow up period, respec-
MMF AZA p value
Patients enrolled 34 34
Recipient’s age (yr) 42.2±12.3 35.4±10.4 .015
Male/female 17/17 19/15  .627
(50%/50%) (55.9%/44.1%)
Primary cause of Renal failure NS
Diabetic nephropathy 6 5
Hypertension/renal vascular 5 3
Glomerulonephritis 4 3
Pyelonephritis 2 1
Polycystic kidney disease 1 1
FSGS 3
Unknown 11 19
Nephrotic syndrome 1
IgA nephropathy 1 2
Pretransplant PRA level (≥20%) 1 (2.9%) 1 (2.9%) .394
Cold ischemic time (min) 360.5±206.7 426.1±215.0 .208
Donor/recipient CMV serologic status .887
positive/positive 27 (79.4%) 27 (79.4%)
positive/negative 1 (2.9%) 1 (2.9%)
negative/positive 3 (8.9%) 4 (11.8%)
negative/negative 1 (2.9%) 0
Not done (donor or recipient) 2 (5.9%) 2 (5.9%)
HLA/A+B+DR mismatch .760
0 7 (20.6%) 6 (17.6%)
1 14 (41.2%) 11 (32.4%)
≥2 13 (38.2%) 17 (50.0%)
ABO compatibility .708
identical 27 (79.4%) 29 (85.3%)
compatible 7 (20.6%) 5 (14.7%)
Table 1. Demographics and clinical characteristics
AZA MMF p value
CMV infections (%) 3 (8.8) 5 (14.7) .709
Rejection (%) 10 (29.4) 7 (20.6) .401
Graft failure (%) 4 (11.8) 5 (14.7) 1.000
Table 2. CMV infection, acute rejection and graft failure after trans-
plantation
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Fig. 1. Comparison of graft survival rate between MMF and AZA
groups: one, three and five years graft survival rates are 91.1%,
82.2%, and 82.2% in MMF group vs. 97.1%, 94.1% and 83.1% in
AZA group, respectively.
log rank=.8064
AZA
MMF
FSGS, focal segmental glomerosclerosis; PRA, panel reactive antibody;
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tively. Death of one patient was reported in the MMF group
during the same period. CMV infection was developed in 3
patients (8.8%) in the MMF group and 5 patients (14.7%)
in the AZA group, not showing a significant difference (Table
2). One, three and five year graft survival rates were 91.1%,
88.2% and 88.2% in the MMF group and 97.1%, 94.1% and
83.1% in the AZA group, respectively (p>0.05) (Fig. 1).
DISCUSSION
The introduction of new immunosuppressive agents has
significantly contributed to improve graft survival rate up to
90% in kidney transplantation. However, acute rejection is
the most common cause of graft loss and a major factor influ-
encing the long-term graft survival rate (1). As shown in sev-
eral studies, in cadaveric renal transplantation, the major fac-
tors which influence the outcome of graft function are divided
into immunologic factors and non-immunologic factors. Im-
munologic factors were reported to affect acute rejection, chro-
nic rejection, and graft survival (2). Non-immunologic factors
also should not be ignored because they are associated with
delayed graft function, rejection, and graft survival (6, 7).
Several comparative studies have reported how immuno-
suppressive agents, which were developed to inhibit immuno-
logic shade, have influenced acute rejection and graft survival.
In particular, previously published data have indicated that
MMF reduced acute rejection rate and improved graft survival
during the early post-transplant period compared to AZA
(5, 8). However, finding a study that considered the non-im-
munologic factors, especially donor factors is not easy. Thus,
we designed a comparative case-control study to minimize
the influence of donor factors by grafting the same cadaveric
donor kidney.
Two kidney recipients grafted from the same cadaveric donor
were randomized and assigned to either the MMF or AZA
group. They received a triple immunosuppressive regimens,
which consisted of CsA, prednisolon and either MMF or AZA
according to the protocol, and their results such as acute rejec-
tion, graft survival and others were prospectively analyzed
and compared. In summary, no difference was found in sex,
HLA mismatching, weight, cold ischemic time, or underly-
ing disease between the MMF and AZA group, while there
was a significant difference in age factor. Recently data showed
that censored graft survival-which excludes death with func-
tioning graft-and the incidence of rejection episodes was equal
in three adult groups of renal transplanted patients of differ-
ent age (9). And a comparison of graft survival between chil-
dren and elderly adults has been performed recently because
recipient age may have an effect on renal graft survival due
to its potential influence on the competence of the immune
system. Though the incidence of acute rejections appeared
to be significantly higher in the pediatric population, there
was no significant difference in graft survival between both
groups when death with functioning graft was excluded (10).
So even though in our result there was significant difference
in recipient age between two groups by univariate analysis,
this result might be not meaningful because during this study
the mean ages of both groups belong to low risk criteria due
to above 18 yr old. There was no significant difference bet-
ween the two groups in the incidence of acute rejection epi-
sodes and 5 yr graft survival rate. This is different from pre-
vious reports showing that MMF could reduce the incidence
of acute rejection and improve graft survival.
Even though this study has some limitation of a small num-
ber of cases and relatively short-term follow up, these discre-
pant results might imply that donor factors could play an im-
portant role in cadaveric renal transplantation. Accordingly,
donor factors deserve to be considered for the further clinical
studies despite a small number of cases and a short follow-up
period.
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